This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (64)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Drug Therapy, Other  • Pneumonia  • Bacterial Infections  • Alert me on articles by topic

Joseph A. Kovacs, MD; Vee J. Gill, PhD; Steven Meshnick, MD, PhD; Henry Masur, MD

JAMA. 2001;286:2450-2460.

Pneumocystis carinii has been recognized as a human pathogen for nearly 50 years. We present a case of P carinii infection that typifies clinical presentation in the era of the acquired immunodeficiency syndrome epidemic. The high incidence of P carinii pneumonia in persons infected with human immunodeficiency virus (HIV) has served to focus laboratory and clinical research efforts on better understanding the biology of the organism and on improving diagnosis, treatment, and prevention of this disease. Although inability to culture P carinii has hampered research efforts, molecular and immunologic approaches have led to the recognition that the organism represents a family of fungi with a very restricted host range and have allowed characterization of clinically relevant antigens and enzymes. Molecular epidemiologic studies have identified more than 50 strains of human-derived P carinii and have suggested that recently acquired infection, as opposed to reactivation of latent infection, may account for many cases of clinical disease. Diagnosis has been improved by the development of organism-specific monoclonal antibodies and, more recently, by polymerase chain reaction using multicopy gene targets, together with induced sputum or oral wash samples. Chemotherapeutic prophylaxis is very effective in preventing P carinii pneumonia; the combination of trimethoprim-sulfamethoxazole remains the first-line agent for both therapy and prophylaxis. Prophylaxis needs to be administered only during periods of high risk; in HIV-infected patients responding to effective antiretroviral therapies, prophylaxis no longer needs to be lifelong. Molecular studies have identified mutations in the target of sulfa drugs that appear to represent emerging resistance in P carinii. Resistance to atovaquone, a second-line agent, may also be developing.

Author Affiliations: Critical Care Medicine Department (Drs Kovacs and Masur) and Microbiology Service, Department of Laboratory Medicine (Dr Gill), Clinical Center, National Institutes of Health, Bethesda, Md; and Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor (Dr Meshnick).

RELATED ARTICLE

November 21, 2001
JAMA. 2001;286(19):2481-2482.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Immune responses to Pneumocystis murina are robust in healthy mice but largely absent in CD40 ligand-deficient mice
Hernandez-Novoa et al.
J. Leukoc. Biol. 2008;84:420-430.
ABSTRACT | FULL TEXT  

Molecular Evidence of Nosocomial Pneumocystis jirovecii Transmission among 16 Patients after Kidney Transplantation
Schmoldt et al.
J. Clin. Microbiol. 2008;46:966-971.
ABSTRACT | FULL TEXT  

Functional Characterization of Pneumocystis carinii brl1 by Transspecies Complementation Analysis
Lo Presti et al.
Eukaryot Cell 2007;6:2448-2452.
ABSTRACT | FULL TEXT  

Pulmonary Hypertension Can Be a Sequela of Prior Pneumocystis Pneumonia
Swain et al.
Am. J. Pathol. 2007;171:790-799.
ABSTRACT | FULL TEXT  

Inter-laboratory comparison of three different real-time PCR assays for the detection of Pneumocystis jiroveci in bronchoalveolar lavage fluid samples.
Linssen et al.
J Med Microbiol 2006;55:1229-1235.
ABSTRACT | FULL TEXT  

A Review of Pneumocystis Pneumonia
Lee
Journal of Pharmacy Practice 2006;19:5-9.
ABSTRACT  

Complement and Fc Function Are Required for Optimal Antibody Prophylaxis against Pneumocystis carinii Pneumonia
Wells et al.
Infect. Immun. 2006;74:390-393.
ABSTRACT | FULL TEXT  

Ubiquinone Synthesis in Mitochondrial and Microsomal Subcellular Fractions of Pneumocystis spp.: Differential Sensitivities to Atovaquone
Basselin et al.
Eukaryot Cell 2005;4:1483-1492.
ABSTRACT | FULL TEXT  

Mutations in the Pneumocystis jirovecii DHPS Gene Confer Cross-Resistance to Sulfa Drugs
Iliades et al.
Antimicrob. Agents Chemother. 2005;49:741-748.
ABSTRACT | FULL TEXT  

Mutations of Pneumocystis jirovecii Dihydrofolate Reductase Associated with Failure of Prophylaxis
Nahimana et al.
Antimicrob. Agents Chemother. 2004;48:4301-4305.
ABSTRACT | FULL TEXT  

Update in Renal Transplantation
Magee and Pascual
Arch Intern Med 2004;164:1373-1388.
ABSTRACT | FULL TEXT  

Inability of Pneumocystis organisms to incorporate bromodeoxyuridine suggests the absence of a salvage pathway for thymidine
Vestereng and Kovacs
Microbiology 2004;150:1179-1182.
ABSTRACT | FULL TEXT  

Asymptomatic carriage of Pneumocystis jiroveci in subjects undergoing bronchoscopy: a prospective study
Maskell et al.
Thorax 2003;58:594-597.
ABSTRACT | FULL TEXT  

New Considerations for PCP in the Era of Potent Combination Therapy: Sulfa Resistance and Immune Reconstitution
AIDS Clin Care 2003;2003:10-10.
FULL TEXT  

Therapeutic Efficacies of GW471552 and GW471558, Two New Azasordarin Derivatives, against Pneumocystosis in Two Immunosuppressed-Rat Models
Jimenez et al.
Antimicrob. Agents Chemother. 2002;46:2648-2650.
ABSTRACT | FULL TEXT  

Acquired Immunodeficiency Syndrome in the Intensive Care Unit: Will Human Immunodeficiency Virus-related Admissions Continue to Decline?
Masur
Am. J. Respir. Crit. Care Med. 2002;166:258-259.
FULL TEXT